Is tepotinib FDA approved?

In March 2020, tepotinib was first approved in Japan for the treatment of MET-altered non-small cell lung cancer (NSCLC), and subsequently received accelerated approval from the U.S. Food and Drug Administration (FDA) in February 2021 for the treatment of patients with stromal- In February 2022, tepotinib was approved by the European Medicines Agency (EMA) for adult patients with metastatic non-small cell lung cancer (NSCLC) with epithelial transformation (MET) exon 14 skipping alterations. At present, the original drug Tepotinib has not been launched in China, so it has not entered the ranks of medical insurance.